Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

NCT00118040 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00118040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00118040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 24, 2005
Completion date
August 15, 2010
Enrollment
60 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent bladder carcinoma, stage i bladder cancer ajcc v6 and v7, stage ii bladder cancer ajcc v6 and v7, stage iii bladder cancer ajcc v6 and v7